

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF KANSAS**

**IN RE: EpiPen (Epinephrine
Injection, USP) Marketing,
Sales Practices and Antitrust
Litigation**

MDL No: 2785

Case No. 17-md-2785-DDC-TJJ

(This Document Applies to the *Sanofi* case)

SCHEDULING ORDER NO. 3

With this Scheduling Order No. 3, the court establishes the following schedule for plaintiff Sanofi-Aventis U.S. LLC (“Sanofi”) to file its Motion for a Suggestion of Remand.

<u>Event</u>	<u>Deadline</u>
Sanofi’s Motion for a Suggestion of Remand	Thursday, November 1, 2018
Defendants’ Response	Friday, November 30, 2018
Sanofi’s Reply	Friday, December 14, 2018

This modified schedule, with Sanofi’s consent, accelerates Sanofi’s deadline from the one established in Scheduling Order No. 2 ([Doc. 61](#)). The deadlines for defendants’ Response (November 30, 2018) and Sanofi’s Reply (December 14, 2018) are new, as Scheduling Order No. 2 did not address those deadlines. While Sanofi pressed for an earlier response deadline, the court was persuaded that defendants’ proposed deadline was fairer and adopting it would not delay the decision materially.

IT IS SO ORDERED.

Dated September 19, 2018, at Kansas City, Kansas.

s/ Daniel D. Crabtree
Daniel D. Crabtree
U.S. District Judge

s/ Teresa J. James
Teresa J. James
U.S. Magistrate Judge